Clinical Trial Update: F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating F511 Cream to prevent hand-foot syndrome in patients with metastatic breast cancer receiving liposomal doxorubicin.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Palmar-plantar Erythrodysesthesia

Drugs mentioned

• F511 Cream
• liposomal doxorubicin (doxorubicin liposomal)

Snippet

Sponsor: Swiss Cancer Institute | Conditions: Breast Cancer, Palmar-plantar Erythrodysesthesia | Phase 3 | Status: COMPLETED